1,146 results on '"Freedman, Mark S."'
Search Results
2. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial
3. Neurofilaments as biomarkers in neurological disorders — towards clinical application
4. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
5. Identification of brain-enriched proteins in CSF as biomarkers of relapsing remitting multiple sclerosis
6. Assessing multimodal emotion recognition in multiple sclerosis with a clinically accessible measure
7. Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis
8. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis
9. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
10. Predicting time to serologic diagnosis of AQP4+ NMOSD based on clinical factors and social determinants of health
11. MRI graph parameters are longitudinal markers of neuronal integrity in multiple sclerosis
12. Physical Activity Together for Multiple Sclerosis (PAT-MS): A randomized controlled feasibility trial of a dyadic behaviour change intervention
13. A Canadian case control study investigating demographic and environmental factors associated with MOGAD
14. Contributors
15. General Immunization Practices
16. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
17. The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study
18. Health Canada drug approval process: a barrier to personalized care in multiple sclerosis
19. The symbol digit modalities test and the paced auditory serial addition test involve more than processing speed
20. The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
21. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
22. CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent
23. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
24. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study
25. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
26. Investigation of Health Care Use and a Possible Prodrome Before the First Attack in NMOSD and MOGAD
27. Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis
28. Relationship between Metformin, Monoacylglycerol Lipase Expression, Cognition and Emotion Recognition in People with Multiple Sclerosis and Comorbid Type II Diabetes
29. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2020
30. Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study
31. Heightened Precautions for Imported Dogs Vaccinated with Potentially Ineffective Rabies Vaccine--United States, August 2021-April 2024
32. Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis
33. Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
34. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis
35. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
36. From progression to progress: The future of multiple sclerosis.
37. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
38. Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
39. Imaging cognitive fatigability in multiple sclerosis: objective quantification of cerebral blood flow during a task of sustained attention using ASL perfusion fMRI
40. COVID-19 in teriflunomide-treated patients with multiple sclerosis
41. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS
42. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry
43. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★
44. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
45. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study
46. Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
47. Physical Activity Together for People With Multiple Sclerosis and Their Care Partners: Protocol for a Feasibility Randomized Controlled Trial of a Dyadic Intervention
48. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study
49. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
50. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.